AKBAAkebia Therapeutics, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 11543
Ticker: AKBA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2014-03-20
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: AKBA

Detail

Enriched 2026-08-14 20:47

Market cap: $247,511,298.03
Shares outstanding (class): 277,106,245
Shares outstanding (weighted): 277,106,245
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 194
Location: CAMBRIDGE, MA
Homepage: https://www.akebia.com
Description: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Market cap and share counts drift.

Funds holding this security

78 funds · 78 positions · $43.18M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$11.00M	0.00%	7,912,283 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$8.68M	0.01%	6,244,933 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$8.39M	0.11%	6,038,997 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$4.14M	0.01%	2,980,301 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$2.64M	0.02%	1,898,454 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$1.62M	0.04%	1,163,366 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$887.4K	0.07%	638,413 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$585.4K	0.01%	421,156 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$490.5K	0.00%	352,872 NS	FIGI
Virtus Small-Cap Fund Virtus Investment Trust	—	$428.1K	0.40%	308,000 NS	FIGI
Fidelity Small Cap Value Index Fund Fidelity Salem Street Trust	—	$388.7K	0.02%	279,644 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$347.2K	0.01%	249,817 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$329.8K	0.00%	237,280 NS	FIGI
LVIP SSGA Small-Cap Index Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$254.4K	0.01%	183,000 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$210.5K	0.00%	151,441 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERAKBA
FIGI_COMPOSITEBBG000R33R00
FIGI_SHARE_CLASSBBG001T922S9
CIK0001517022
ISINUS00972D1054
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, classified under pharmaceuticals.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.